Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Investor Presentation (February 2026)
16 slides from Avita Medical's investor presentation, Feb 16, 2026
Slide 1: AVITA Medical Investor Briefing February 2026
For personal use only AVITA Medical Investor Briefing February 2026
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These For personal use only statements are predictions and subject to si
Slide 3: Delivering on Q4 2025 priorities, positioned for growth in 2026
Delivering on Q4 2025 priorities, positioned for growth in 2026 Drive disciplined execution For personal use only o Business stabilized; execution phase underway o Year-end growth sustained with greater than 80% gross margin Refine our commercial focus o Commercial model oriented to organic core-acc
Slide 4: MAC action on provider reimbursement addresses major headwind
MAC action on provider reimbursement addresses major headwind RECELL data and provider reimbursement are now aligned AVITA actions underway to accelerate to restore use and adoption awareness of published rates For personal use only Data Reimbursement • Active Communication with hospitals and clinic
Slide 5: Financial results reflecting full year revenue growth and cost discipline
Financial results reflecting full year revenue growth and cost discipline FY Key figures Q4 Q4 FY FY 2026 For personal use only USD million 2024 2025 2024 2025 (Estimate) Revenue $18.4 $17.6 $64.3 $71.6 $80 to $85 Gross profit margin* 87.6% 81.2% 85.8% 82.1% Operating $26.1 $24.7** $111.8 $101.4 exp
Slide 6: AVITA continued sales growth with above 80% gross margin
AVITA continued sales growth with above 80% gross margin Net Revenue Gross margin For personal use only USD million 82.0% 82.0% 82.4% 84.5% 85.8% 82.1%* +32% +11% +28% +46% +35% +46% 18 2020** 2021** 2022 2023 2024 2025 2020** 2021** 2022 2023 2024 2025 USD mn 18 26 35 50 64 72 *Decrease in gross ma
Slide 7: Continued focus on cash use
Continued focus on cash use Cash, and marketable securities at quarter end For personal use only USD million Cash use $10.1 Cash use $6.2 Cash use $5.1 $13.8 Equity raise* $25.8 $23.3 $18.2 $15.7 Q1 Q2 Q3 Q4 *Raised $13.8 million, net after expenses, through a private placement completed in August A
Slide 8: New debt facility with Perceptive Advisors LLC on better terms
New debt facility with Perceptive Advisors LLC on better terms Key loan terms Rationale For personal use only Amount: $60 million ($50 million at close); optional $10 million Maturity: 5 years from close Refinance existing debt on better terms Interest rate: SOFR + 7.5% Amortization: None, interest
Slide 9: Three differentiated products solving distinct problems in acute wound care
Three differentiated products solving distinct problems in acute wound care For personal use only PermeaDerm® is a temporary, RECELL®, RECELL GO and Cohealyx is a collagen dermal transparent biosynthetic RECELL GO mini convert a small matrix that enables wound matrix that stabilizes sample of a pati
Slide 10: How Surgeons Are Using the Portfolio
How Surgeons Are Using the Portfolio Deep Partial-Thickness Wound Full-Thickness Wound Partial-Thickness Wound Deep Partial-Thickness Wound Full-Thickness Wound For personal use only Stabilize and protect Stabilize, restore and protect Stabilize, rebuild, restore and protect Clinical intent: Clinica
Slide 11: A large acute wound market served through a focused strategy at ~200 high-volume centers
A large acute wound market served through a focused strategy at ~200 high-volume centers Large addressable market with low current Execution priorities focused on utilization, For personal use only penetration and clear runway portfolio pull-through and select expansion AVITA Focus Accelerate revenu
Slide 12: We continue to deliver real world clinical evidence to support growth
We continue to deliver real world clinical evidence to support growth Acute wound Preclinical mechanism of action 2025 For personal use only growth drivers Presentations Partial thickness burns randomized control trial (n=67) • Establish RECELL as (Select examples) standard of care RECELL GO vs Ease
Slide 13: First use of full portfolio for full-thickness wound management
First use of full portfolio for full-thickness wound management Case* presented by Dr. Neil Mashruwala, Carle Bromenn Medical Center For personal use only 91 yr old female│ Morel-Lavallée Lesion of left lower leg 300 cm², 1 cm deep Donor Site Injury Injury *Integrated Use of Advanced Wound Care Tech
Slide 14: First use of full portfolio for full-thickness wound management
First use of full portfolio for full-thickness wound management Injury + excision Cohealyx treatment 3:1 mSTSG + RECELL For personal use only POD 22 Donor Site 14 AVITA Medical | February 2026
Slide 15: Summary
Summary For personal use only Delivered a more Exited 2025 with Advanced post- Entered 2026 with stable revenue reimbursement market clinical an improved performance in Q4, clarity and early signs programs and commercial model with improved of RECELL utilization presentations for and capital visibil
Slide 16: For personal use only
For personal use only
AVITA Medical — Investor Presentation (February 2026) on 6ix